CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis

NCT01325194 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

NETWORK

Sponsor class

Conditions

Primary Disease

Interventions

DRUG: liposomal cytarabine

Sponsor

Nordic Lymphoma Group

Collaborators

[object Object]
[object Object]